person · Reporting owner

Kassberg Thomas Richard

Disclosed activity across 2 companies

Tapewire entity: 45188
SEC CIK: 0001303811

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Passage BIO, Inc.PASG · Entity 7829	Director	May 19, 2026	May 21, 2026
Ultragenyx Pharmaceutical Inc.RARE · Entity 4337	CBO & EVP	March 01, 2025	March 05, 2025

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Passage BIO, Inc.

Report date May 19, 2026 · Filed May 21, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.08 · Expires 2036-05-19	Direct	10,539	Reported balance After 2026-05-19 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-05-19 · Grant · Acquired 10,539 · Balance 10,539 F1: The stock option vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2027 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date.

Filing footnotes · ownership attribution and instrument terms

F1: The stock option vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2027 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date.

Ultragenyx Pharmaceutical Inc.

Report date March 01, 2025 · Filed March 05, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	271,266	Reported balance After 2025-03-01 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2025-03-01 · Grant · Acquired 18,443 · Balance 271,266 F1: Represents shares of common stock which previously granted performance stock units were converted on March 1, 2025 upon certification of the performance metric.
Common StockSEC Table I · non-derivative	Direct	265,238	Reported balance After 2025-03-03 transaction · row 2 Account or security details depend on footnotes; rows are not merged. 1 source row Row 2 · 2025-03-03 · Sale · Disposed 6,028 · Balance 265,238 F2: Represents shares sold to pay required tax withholdings due to the vesting of RSUs. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.77 to $42.90 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Common StockSEC Table I · non-derivative	Direct	264,730	Reported balance After 2025-03-03 transaction · row 3 Account or security details depend on footnotes; rows are not merged. 1 source row Row 3 · 2025-03-03 · Tax withholding · Disposed 508 · Balance 264,730 F4: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs. F5: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares of common stock which previously granted performance stock units were converted on March 1, 2025 upon certification of the performance metric.

F2: Represents shares sold to pay required tax withholdings due to the vesting of RSUs.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.77 to $42.90 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F4: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs.

F5: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
May 19, 2026 Filed May 21, 2026 20:13 UTC	Passage BIO, Inc. PASG · Entity 7829	GrantDirector Stock Option (right to buy) · Derivative	10,539	$0.00 Strike: $5.08	$0.00	Disclosure SEC source: 0001303811-26-000002 · form4-05212026_080558.xml · derivative · entry 1 Kassberg Thomas Richard · CIK 0001303811 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,539 Underlying: Common Stock · 10,539 shares Expires 2036-05-19 F1 · derivative.exercise_date: The stock option vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2027 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date. Read SEC document
May 28, 2025 Filed May 30, 2025 23:26 UTC	Passage BIO, Inc. PASG · Entity 7829	GrantDirector Stock Option (right to buy) · Derivative	143,789	$0.00 Strike: $0.36	$0.00	Disclosure SEC source: 0001415889-25-015054 · form4-05302025_110528.xml · derivative · entry 1 Kassberg Thomas Richard · CIK 0001303811 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 143,789 Underlying: Common Stock · 143,789 shares Expires 2035-05-28 F1 · derivative.exercise_date: The stock option vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2026 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date. Read SEC document
March 03, 2025 Filed Mar 5, 2025 01:19 UTC	Ultragenyx Pharmaceutical Inc. RARE · Entity 4337	Tax withholdingCommon Stock	508	$42.92	$21,803.36	Disclosure SEC source: 0000950170-25-032802 · ownership.xml · nonDerivative · entry 3 Kassberg Thomas Richard · CIK 0001303811 · CBO & EVP 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 264,730 F4 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs. F5 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document
March 03, 2025 Filed Mar 5, 2025 01:19 UTC	Ultragenyx Pharmaceutical Inc. RARE · Entity 4337	SaleCommon Stock	6,028	$42.10	$253,778.80	Disclosure SEC source: 0000950170-25-032802 · ownership.xml · nonDerivative · entry 2 Kassberg Thomas Richard · CIK 0001303811 · CBO & EVP 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 265,238 F2 · shares: Represents shares sold to pay required tax withholdings due to the vesting of RSUs. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.77 to $42.90 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
March 01, 2025 Filed Mar 5, 2025 01:19 UTC	Ultragenyx Pharmaceutical Inc. RARE · Entity 4337	GrantCommon Stock	18,443	$0.00	$0.00	Disclosure SEC source: 0000950170-25-032802 · ownership.xml · nonDerivative · entry 1 Kassberg Thomas Richard · CIK 0001303811 · CBO & EVP 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 271,266 F1 · shares: Represents shares of common stock which previously granted performance stock units were converted on March 1, 2025 upon certification of the performance metric. Read SEC document
September 30, 2024 Filed Oct 2, 2024 20:35 UTC	Passage BIO, Inc. PASG · Entity 7829	GrantEmployee Stock Option (right to buy) · Derivative	174,139	$0.00 Strike: $0.70	$0.00	Disclosure SEC source: 0001415889-24-024416 · form4-10022024_081016.xml · derivative · entry 1 Kassberg Thomas Richard · CIK 0001303811 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 174,139 Underlying: Common Stock · 174,139 shares Expires 2034-09-30 F1 · derivative.exercise_date: The stock option vests as to 1/36 of the total shares monthly beginning on October 10, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document
March 11, 2024 Filed Mar 12, 2024 17:41 UTC	Ultragenyx Pharmaceutical Inc. RARE · Entity 4337	SaleCommon Stock	11,509	$49.93	$574,644.37	Disclosure SEC source: 0000950170-24-029780 · ownership.xml · nonDerivative · entry 1 Kassberg Thomas Richard · CIK 0001303811 · CBO & EVP 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 252,823 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.92 to $50.06 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document
March 01, 2024 Filed Mar 6, 2024 01:19 UTC	Ultragenyx Pharmaceutical Inc. RARE · Entity 4337	GrantStock Option (Right to Buy) · Derivative	31,400	$0.00 Strike: $53.69	$0.00	Disclosure SEC source: 0000950170-24-026661 · ownership.xml · derivative · entry 5 Kassberg Thomas Richard · CIK 0001303811 · CBO & EVP 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,400 Underlying: Common Stock · 31,400 shares Expires 2034-03-01 F6 · derivative.exercise_date: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date. Read SEC document
March 01, 2024 Filed Mar 6, 2024 01:19 UTC	Ultragenyx Pharmaceutical Inc. RARE · Entity 4337	SaleCommon Stock	1,011	$53.76	$54,351.36	Disclosure SEC source: 0000950170-24-026661 · ownership.xml · nonDerivative · entry 4 Kassberg Thomas Richard · CIK 0001303811 · CBO & EVP 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 264,332 F4 · shares: Represents shares sold to pay required tax withholdings due to the vesting of RSUs. F5 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document
March 01, 2024 Filed Mar 6, 2024 01:19 UTC	Ultragenyx Pharmaceutical Inc. RARE · Entity 4337	Tax withholdingCommon Stock	274	$53.69	$14,711.06	Disclosure SEC source: 0000950170-24-026661 · ownership.xml · nonDerivative · entry 3 Kassberg Thomas Richard · CIK 0001303811 · CBO & EVP 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 265,343 F3 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs. Read SEC document
March 01, 2024 Filed Mar 6, 2024 01:19 UTC	Ultragenyx Pharmaceutical Inc. RARE · Entity 4337	GrantCommon Stock	957	$0.00	$0.00	Disclosure SEC source: 0000950170-24-026661 · ownership.xml · nonDerivative · entry 2 Kassberg Thomas Richard · CIK 0001303811 · CBO & EVP 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 265,617 F2 · shares: Represents shares of common stock which previously granted performance stock units were converted on March 1, 2024 upon certification of the performance metric. Read SEC document
March 01, 2024 Filed Mar 6, 2024 01:19 UTC	Ultragenyx Pharmaceutical Inc. RARE · Entity 4337	GrantCommon Stock	17,800	$0.00	$0.00	Disclosure SEC source: 0000950170-24-026661 · ownership.xml · nonDerivative · entry 1 Kassberg Thomas Richard · CIK 0001303811 · CBO & EVP 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 264,660 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date Read SEC document
October 23, 2023 Filed Oct 24, 2023 21:22 UTC	Ultragenyx Pharmaceutical Inc. RARE · Entity 4337	Exercise / conversionStock Option (Right to Buy) · Derivative	39,878	$0.00 Strike: $6.86	$0.00	Disclosure SEC source: 0001209191-23-053487 · doc4.xml · derivative · entry 3 Kassberg Thomas Richard · CIK 0001303811 · CBO & EVP 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 39,878 shares Expires 2023-10-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested with respect to 1/4th of the shares on the first anniversary of the grant date of the option and 1/48th of the shares thereafter such that the option fully vested on the fourth anniversary of the grant date. Read SEC document
October 23, 2023 Filed Oct 24, 2023 21:22 UTC	Ultragenyx Pharmaceutical Inc. RARE · Entity 4337	SaleCommon Stock	39,878	$32.78	$1,307,200.84	Disclosure SEC source: 0001209191-23-053487 · doc4.xml · nonDerivative · entry 2 Kassberg Thomas Richard · CIK 0001303811 · CBO & EVP 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 246,860 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.09 to $33.18 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document
October 23, 2023 Filed Oct 24, 2023 21:22 UTC	Ultragenyx Pharmaceutical Inc. RARE · Entity 4337	Exercise / conversionCommon Stock	39,878	$6.86	$273,563.08	Disclosure SEC source: 0001209191-23-053487 · doc4.xml · nonDerivative · entry 1 Kassberg Thomas Richard · CIK 0001303811 · CBO & EVP 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 286,738 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 01, 2023 Filed Mar 4, 2023 00:57 UTC	Ultragenyx Pharmaceutical Inc. RARE · Entity 4337	GrantStock Option (Right to Buy) · Derivative	39,400	$0.00 Strike: $45.65	$0.00	Disclosure SEC source: 0001209191-23-016046 · doc4.xml · derivative · entry 5 Kassberg Thomas Richard · CIK 0001303811 · CBO & EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,400 Underlying: Common Stock · 39,400 shares Expires 2033-03-01 F6 · derivative.exercise_date: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date. Read SEC document
March 01, 2023 Filed Mar 4, 2023 00:57 UTC	Ultragenyx Pharmaceutical Inc. RARE · Entity 4337	Disposition to issuerCommon Stock	3,394	$45.65	$154,936.10	Disclosure SEC source: 0001209191-23-016046 · doc4.xml · nonDerivative · entry 4 Kassberg Thomas Richard · CIK 0001303811 · CBO & EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,860 F4 · shares: Shares were acquired upon the partial vesting of a previously reported RSU and were sold to permit the cash value of the awards to be credited to the deferred compensation plan account of the Reporting Person F5 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document
March 01, 2023 Filed Mar 4, 2023 00:57 UTC	Ultragenyx Pharmaceutical Inc. RARE · Entity 4337	SaleCommon Stock	1,968	$45.27	$89,091.36	Disclosure SEC source: 0001209191-23-016046 · doc4.xml · nonDerivative · entry 3 Kassberg Thomas Richard · CIK 0001303811 · CBO & EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,254 F3 · shares: Represents shares sold to pay required tax withholdings due to the vesting of RSUs. Read SEC document
March 01, 2023 Filed Mar 4, 2023 00:57 UTC	Ultragenyx Pharmaceutical Inc. RARE · Entity 4337	GrantCommon Stock	22,000	$0.00	$0.00	Disclosure SEC source: 0001209191-23-016046 · doc4.xml · nonDerivative · entry 2 Kassberg Thomas Richard · CIK 0001303811 · CBO & EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 252,222 F2 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date. Read SEC document
March 01, 2023 Filed Mar 4, 2023 00:57 UTC	Ultragenyx Pharmaceutical Inc. RARE · Entity 4337	GrantCommon Stock	2,663	$0.00	$0.00	Disclosure SEC source: 0001209191-23-016046 · doc4.xml · nonDerivative · entry 1 Kassberg Thomas Richard · CIK 0001303811 · CBO & EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,222 F1 · shares: Represents shares of common stock which previously granted performance stock units were converted on March 1, 2023 upon certification of the performance metric. Read SEC document
March 11, 2022 Filed Mar 15, 2022 20:33 UTC	Ultragenyx Pharmaceutical Inc. RARE · Entity 4337	SaleCommon Stock	10,281	$67.01	$688,929.81	Disclosure SEC source: 0001209191-22-018829 · doc4.xml · nonDerivative · entry 1 Kassberg Thomas Richard · CIK 0001303811 · CBO & EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 227,559 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.00 to $67.15 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document
March 01, 2022 Filed Mar 3, 2022 23:07 UTC	Ultragenyx Pharmaceutical Inc. RARE · Entity 4337	GrantStock Option (Right to Buy) · Derivative	24,900	$0.00 Strike: $67.37	$0.00	Disclosure SEC source: 0001209191-22-015806 · doc4.xml · derivative · entry 3 Kassberg Thomas Richard · CIK 0001303811 · CBO & EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,900 Underlying: Common Stock · 24,900 shares Expires 2032-03-01 F4 · derivative.exercise_date: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date. Read SEC document
March 01, 2022 Filed Mar 3, 2022 23:07 UTC	Ultragenyx Pharmaceutical Inc. RARE · Entity 4337	GrantCommon Stock	14,000	$0.00	$0.00	Disclosure SEC source: 0001209191-22-015806 · doc4.xml · nonDerivative · entry 2 Kassberg Thomas Richard · CIK 0001303811 · CBO & EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 227,840 F2 · shares: Award of RSUs under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date. F3 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document
March 01, 2022 Filed Mar 3, 2022 23:07 UTC	Ultragenyx Pharmaceutical Inc. RARE · Entity 4337	SaleCommon Stock	2,374	$66.62	$158,155.88	Disclosure SEC source: 0001209191-22-015806 · doc4.xml · nonDerivative · entry 1 Kassberg Thomas Richard · CIK 0001303811 · CBO & EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,840 F1 · kind: Represents shares sold to pay required tax withholdings due to the vesting of Restricted Stock Units ("RSUs"). Read SEC document
December 10, 2021 Filed Feb 1, 2022 18:42 UTC	Ultragenyx Pharmaceutical Inc. RARE · Entity 4337	GiftCommon Stock	52	$0.00	$0.00	Disclosure SEC source: 0001209191-22-005840 · doc5.xml · nonDerivative · entry 1 Kassberg Thomas Richard · CIK 0001303811 · CBO & EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,214 F1 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document
October 14, 2021 Filed Oct 18, 2021 22:48 UTC	Ultragenyx Pharmaceutical Inc. RARE · Entity 4337	SaleCommon Stock	286	$81.14	$23,206.04	Disclosure SEC source: 0001209191-21-060754 · doc4.xml · nonDerivative · entry 1 Kassberg Thomas Richard · CIK 0001303811 · CBO & EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,266 F1 · kind: Represents shares sold to pay required tax withholdings due to the vesting of Restricted Stock Units ("RSUs"). F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document
September 30, 2021 Filed Oct 1, 2021 16:57 UTC	Ultragenyx Pharmaceutical Inc. RARE · Entity 4337	Exercise / conversionStock Option (Right to Buy) · Derivative	109,734	$0.00 Strike: $0.31	$0.00	Disclosure SEC source: 0001209191-21-058365 · doc4.xml · derivative · entry 2 Kassberg Thomas Richard · CIK 0001303811 · CBO & EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 109,734 shares Expires 2021-11-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vested with respect to 1/4th of the shares on the first anniversary of the grant date of the option and 1/48th of the shares thereafter such that the option fully vested on the fourth anniversary of the grant date. Read SEC document
September 30, 2021 Filed Oct 1, 2021 16:57 UTC	Ultragenyx Pharmaceutical Inc. RARE · Entity 4337	Exercise / conversionCommon Stock	109,734	$0.31	$34,017.54	Disclosure SEC source: 0001209191-21-058365 · doc4.xml · nonDerivative · entry 1 Kassberg Thomas Richard · CIK 0001303811 · CBO & EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,552 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document
May 06, 2021 Filed May 10, 2021 22:11 UTC	Ultragenyx Pharmaceutical Inc. RARE · Entity 4337	SaleCommon Stock	363	$113.69	$41,269.47	Disclosure SEC source: 0001209191-21-031384 · doc4.xml · nonDerivative · entry 1 Kassberg Thomas Richard · CIK 0001303811 · CBO & EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,818 F1 · kind: Represents shares sold to pay required tax withholdings due to the vesting of RSUs. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document
March 01, 2021 Filed Mar 4, 2021 01:55 UTC	Ultragenyx Pharmaceutical Inc. RARE · Entity 4337	GrantStock Option (Right to Buy) · Derivative	11,000	$0.00 Strike: $142.47	$0.00	Disclosure SEC source: 0001209191-21-017567 · doc4.xml · derivative · entry 4 Kassberg Thomas Richard · CIK 0001303811 · CBO & EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2031-03-01 F7 · derivative.exercise_date: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date. Read SEC document
March 01, 2021 Filed Mar 4, 2021 01:55 UTC	Ultragenyx Pharmaceutical Inc. RARE · Entity 4337	SaleCommon Stock	4,572	$138.17	$631,713.24	Disclosure SEC source: 0001209191-21-017567 · doc4.xml · nonDerivative · entry 3 Kassberg Thomas Richard · CIK 0001303811 · CBO & EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,181 F3 · kind: Represents shares sold to pay required tax withholdings due to the vesting of RSUs. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $138.16 to $138.17 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F5 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. F6 · balance_after: Includes 139 shares acquired under the Company's 2014 Employee Stock Purchase Plan on October 31, 2020. Read SEC document
March 01, 2021 Filed Mar 4, 2021 01:55 UTC	Ultragenyx Pharmaceutical Inc. RARE · Entity 4337	GrantCommon Stock	4,636	$0.00	$0.00	Disclosure SEC source: 0001209191-21-017567 · doc4.xml · nonDerivative · entry 2 Kassberg Thomas Richard · CIK 0001303811 · CBO & EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,614 F2 · shares: Represents 1,530 shares of common stock and 3,106 RSUs into which previously granted performance stock units were converted on March 1, 2021 upon certification of the performance metric. The RSUs will fully vest on March 1, 2022. Read SEC document
March 01, 2021 Filed Mar 4, 2021 01:55 UTC	Ultragenyx Pharmaceutical Inc. RARE · Entity 4337	GrantCommon Stock	5,500	$0.00	$0.00	Disclosure SEC source: 0001209191-21-017567 · doc4.xml · nonDerivative · entry 1 Kassberg Thomas Richard · CIK 0001303811 · CBO & EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,978 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date. Read SEC document
October 14, 2020 Filed Oct 16, 2020 23:20 UTC	Ultragenyx Pharmaceutical Inc. RARE · Entity 4337	SaleCommon Stock	262	$87.98	$23,050.76	Disclosure SEC source: 0001209191-20-055178 · doc4.xml · nonDerivative · entry 1 Kassberg Thomas Richard · CIK 0001303811 · CBO & EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,478 F1 · shares: Represents shares sold to pay required tax withholdings due to the vesting of Restricted Stock Units ("RSUs"). F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document
June 01, 2020 Filed Jun 3, 2020 18:18 UTC	Ultragenyx Pharmaceutical Inc. RARE · Entity 4337	Tax withholdingCommon Stock	348	$69.38	$24,144.24	Disclosure SEC source: 0001209191-20-033884 · doc4.xml · nonDerivative · entry 1 Kassberg Thomas Richard · CIK 0001303811 · CBO & EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,740 F1 · shares: Represents shares sold to pay required tax withholdings due to the vesting of Restricted Stock Units ("RSUs"). F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. F3 · balance_after: Includes 413 shares acquired under the Company's 2014 Employee Stock Purchase Plan on April 30, 2020. Read SEC document
May 06, 2020 Filed May 9, 2020 00:04 UTC	Ultragenyx Pharmaceutical Inc. RARE · Entity 4337	Tax withholdingCommon Stock	248	$66.26	$16,432.48	Disclosure SEC source: 0001209191-20-028112 · doc4.xml · nonDerivative · entry 1 Kassberg Thomas Richard · CIK 0001303811 · CBO & EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,675 F1 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of Restricted Stock Units ("RSUs"). F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document
April 19, 2020 Filed Apr 21, 2020 19:35 UTC	Ultragenyx Pharmaceutical Inc. RARE · Entity 4337	Tax withholdingCommon Stock	248	$58.57	$14,525.36	Disclosure SEC source: 0001209191-20-025190 · doc4.xml · nonDerivative · entry 1 Kassberg Thomas Richard · CIK 0001303811 · CBO & EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,923 F1 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of Restricted Stock Units ("RSUs"). F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document
March 01, 2020 Filed Mar 4, 2020 00:47 UTC	Ultragenyx Pharmaceutical Inc. RARE · Entity 4337	GrantStock Option (Right to Buy) · Derivative	20,000	$0.00 Strike: $56.08	$0.00	Disclosure SEC source: 0001209191-20-015739 · doc4.xml · derivative · entry 4 Kassberg Thomas Richard · CIK 0001303811 · CBO & EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-03-01 F6 · derivative.exercise_date: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date. Read SEC document
March 01, 2020 Filed Mar 4, 2020 00:47 UTC	Ultragenyx Pharmaceutical Inc. RARE · Entity 4337	Tax withholdingCommon Stock	2,067	$56.08	$115,917.36	Disclosure SEC source: 0001209191-20-015739 · doc4.xml · nonDerivative · entry 3 Kassberg Thomas Richard · CIK 0001303811 · CBO & EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,171 F4 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. F5 · balance_after: Includes 129 shares acquired under the Company's 2014 Employee Stock Purchase Plan on October 31, 2019. Read SEC document
March 01, 2020 Filed Mar 4, 2020 00:47 UTC	Ultragenyx Pharmaceutical Inc. RARE · Entity 4337	GrantCommon Stock	5,634	$0.00	$0.00	Disclosure SEC source: 0001209191-20-015739 · doc4.xml · nonDerivative · entry 2 Kassberg Thomas Richard · CIK 0001303811 · CBO & EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,109 F3 · shares: Represents 1,859 shares of common stock and 3,775 RSUs into which previously granted performance stock units were converted on March 1, 2020 upon certification of the performance metric. The RSUs will fully vest on March 1, 2021. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document
March 01, 2020 Filed Mar 4, 2020 00:47 UTC	Ultragenyx Pharmaceutical Inc. RARE · Entity 4337	GrantCommon Stock	6,800	$0.00	$0.00	Disclosure SEC source: 0001209191-20-015739 · doc4.xml · nonDerivative · entry 1 Kassberg Thomas Richard · CIK 0001303811 · CBO & EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,475 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document
October 14, 2019 Filed Oct 16, 2019 23:29 UTC	Ultragenyx Pharmaceutical Inc. RARE · Entity 4337	GrantCommon Stock	1,434	$0.00	$0.00	Disclosure SEC source: 0001209191-19-053325 · doc4.xml · nonDerivative · entry 1 Kassberg Thomas Richard · CIK 0001303811 · CBO & EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,675 F1 · shares: Represents restricted stock units (RSUs) into which previously granted performance stock units were converted on October 14, 2019 upon certification of the applicable performance metric. Half of these RSUs will vest on the first anniversary of the certification date and the other half will vest on the second anniversary of the certification date. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document
June 01, 2019 Filed Jun 4, 2019 22:56 UTC	Ultragenyx Pharmaceutical Inc. RARE · Entity 4337	Tax withholdingCommon Stock	346	$54.93	$19,005.78	Disclosure SEC source: 0001209191-19-034548 · doc4.xml · nonDerivative · entry 1 Kassberg Thomas Richard · CIK 0001303811 · CBO & EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,241 F1 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document
May 21, 2019 Filed May 22, 2019 21:41 UTC	Ultragenyx Pharmaceutical Inc. RARE · Entity 4337	Tax withholdingCommon Stock	381	$59.50	$22,669.50	Disclosure SEC source: 0001209191-19-032135 · doc4.xml · nonDerivative · entry 1 Kassberg Thomas Richard · CIK 0001303811 · CBO & EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,587 F1 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document
May 06, 2019 Filed May 7, 2019 22:50 UTC	Ultragenyx Pharmaceutical Inc. RARE · Entity 4337	GrantCommon Stock	1,434	$0.00	$0.00	Disclosure SEC source: 0001209191-19-028087 · doc4.xml · nonDerivative · entry 1 Kassberg Thomas Richard · CIK 0001303811 · CBO & EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,968 F1 · shares: Represents restricted stock units (RSUs) into which previously granted performance stock units were converted on May 6, 2019 upon certification of the applicable performance metric. Half of these RSUs will vest on the first anniversary of the certification date and the other half will vest on the second anniversary of the certification date. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. F3 · balance_after: Includes 308 shares acquired under the Company's 2014 Employee Stock Purchase Plan on April 30, 2019. Read SEC document
April 19, 2019 Filed Apr 23, 2019 22:20 UTC	Ultragenyx Pharmaceutical Inc. RARE · Entity 4337	Tax withholdingCommon Stock	248	$64.43	$15,978.64	Disclosure SEC source: 0001209191-19-025609 · doc4.xml · nonDerivative · entry 1 Kassberg Thomas Richard · CIK 0001303811 · CBO & EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,226 F1 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document
March 05, 2019 Filed Apr 17, 2019 22:05 UTC Amendment	Ultragenyx Pharmaceutical Inc. RARE · Entity 4337	SaleCommon Stock	832	$65.52	$54,512.64	Disclosure SEC source: 0001209191-19-025125 · doc4a.xml · nonDerivative · entry 2 Kassberg Thomas Richard · CIK 0001303811 · CBO & EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,474 F4 · shares: Represents shares sold to pay required tax withholdings due to the vesting of Restricted Stock Units. Read SEC document
March 01, 2019 Filed Mar 4, 2019 22:05 UTC	Ultragenyx Pharmaceutical Inc. RARE · Entity 4337	GrantStock Option (Right to Buy) · Derivative	21,500	$0.00 Strike: $67.55	$0.00	Disclosure SEC source: 0001209191-19-015736 · doc4.xml · derivative · entry 3 Kassberg Thomas Richard · CIK 0001303811 · CBO & EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,500 Underlying: Common Stock · 21,500 shares Expires 2029-03-01 F5 · derivative.exercise_date: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date. Read SEC document
March 01, 2019 Filed Mar 4, 2019 22:05 UTC	Ultragenyx Pharmaceutical Inc. RARE · Entity 4337	Tax withholdingCommon Stock	806	$67.55	$54,445.30	Disclosure SEC source: 0001209191-19-015736 · doc4.xml · nonDerivative · entry 2 Kassberg Thomas Richard · CIK 0001303811 · CBO & EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,499 F4 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs. Read SEC document
March 01, 2019 Filed Mar 4, 2019 22:05 UTC	Ultragenyx Pharmaceutical Inc. RARE · Entity 4337	GrantCommon Stock	7,000	$0.00	$0.00	Disclosure SEC source: 0001209191-19-015736 · doc4.xml · nonDerivative · entry 1 Kassberg Thomas Richard · CIK 0001303811 · CBO & EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,305 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. F3 · balance_after: Includes 191 shares acquired under the Company's 2014 Employee Stock Purchase Plan. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.